High adiponectin levels, both in plasma and under in vitro conditions, inhibit liver fibrosis, reduce the content of pro-inflammatory interleukin-1β (IL-1β), and promote anti-inflammatory interleukin-10 (IL-10), while low levels of adiponectin contribute to hepatic steatosis, inflammation, fibrosis, and metabolic disorders such as insulin resistance and type 2 diabetes (Al-Nbaheen 2022; Handy et al. 2011; Hotta et al. 2001, 2000; Kitamoto et al. 2015; Saxena and Anania 2015; Wolf et al. 2004). Here, ADIPOQ is linked to metabolic disease.